{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Anixa Biosciences, Inc.
Is Anixa Biosciences, Inc. technically bullish or bearish?
As of June 10, 2025, Anixa Biosciences, Inc. shows a mildly bullish trend supported by positive MACD and Bollinger Bands across multiple time frames, despite some short-term caution from daily moving averages.
Who are in the management team of Anixa Biosciences, Inc.?
As of March 2022, Anixa Biosciences, Inc.'s management team includes Dr. Amit Kumar as Chairman, President, and CEO, with Mr. Lewis Titterton as Lead Independent Director and Dr. Arnold Baskies, Mr. David Cavalier, Ms. Emily Gottschalk, and Dr. John Monahan as Independent Directors.
What does Anixa Biosciences, Inc. do?
Anixa Biosciences, Inc. is a biotechnology company focused on cancer immunotherapy and diagnostics. As of April 2025, it has a market cap of $118.54 million and reported a quarterly net profit loss of $3 million.
How big is Anixa Biosciences, Inc.?
As of Jun 18, Anixa Biosciences, Inc. has a market capitalization of 118.54 million and reported net sales of 0.00 million with a net profit of -12.24 million over the last four quarters. As of Oct 24, the company has shareholder's funds of 20.00 million and total assets of 21.59 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
